BRIEF

on BLUELINEA (EPA:ALBLU)

Bluelinea: 2025 Results and Q1 2026 Performance

Stock price chart of BLUELINEA (EPA:ALBLU) showing fluctuations.

Bluelinea announced revenue of €10,395k for 2025, representing a 10% increase compared to the previous year. This growth is primarily due to the Serenea® business for healthcare facilities, which saw a 33% increase. However, EBITDA declined slightly by 24% to €712k, impacted by the transition to more expensive connected equipment. Despite this, EBITDA remained positive for the fourth consecutive year.

Debt reduction was significant thanks to strong support from the majority shareholder, the APICIL Group. Shareholders' equity doubled to €2,855k, and net debt decreased by 33%, falling back to €2,477k.

For the first quarter of 2026, revenue decreased by 15%, reaching €2,374k, impacted by challenging economic conditions. Bluelinea is implementing several strategic initiatives to strengthen the future growth of its Senior & Home and Institutional divisions.

R. E.

Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all BLUELINEA news